Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$41.71 USD

41.71
3,332,742

+0.28 (0.68%)

Updated Aug 23, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (90 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Novartis (NVS) Q3 Earnings & Sales Top on New Drugs Strength

Novartis AG (NVS) third-quarter results topped estimates driven by strong performance of Cosentyx and Entresto.

    Key Predictions for Q3 Earnings Reports of LLY, BIIB, NVS

    The pharma/biotech industry has seen a solid start to the Q3 earnings season as evident from J&J's solid results. Let's see if the other leading players -- Lilly, Biogen and Novartis -- follow suit.

      Roche (RHHBY) Reports Sales Numbers for First 9 Months

      Roche Holding AG's (RHHBY) reported sales of CHF39.4 billion in the first nine months of 2017, up 5% from the year-ago period.

        BioLineRx/Roche Scan BL-8040-Tecentriq for Gastric Cancer

        BioLineRx (BLRX) and partner Genentech initiate a phase Ib/II study to evaluate the company's lead pipeline candidate, BL-8040, in combination with Tecentriq for treating gastric cancer.

          Biogen (BIIB) Q3 Earnings: Will it Deliver a Beat Again?

          At Biogen's (BIIB) Q3 call, investor focus will remain on Tecfidera's scrip trends, pipeline progress and acquisition plans. All eyes will also be on Spinraza's performance in the same quarter.

            ImmunoGen to Push Leukemia Candidate into Phase I Trial

            ImmunoGen (IMGN) plans to move its leukemia candidate, IMGN632, into phase I study before the year ends. Also, the FDA has completed the safety review of its IND application for IMGN632.

              Inovio Initiates Bladder Cancer Study With Roche's Tecentriq

              Inovio Pharmaceuticals (INO) will evaluate a combination of checkpoint inhibitor and T cell activator as a potential treatment for advanced bladder cancer in a new early stage study.

                FDA Grants Priority Review for Exelixis' RCC Drug Cabomteyx

                Exelixis (EXEL) announced that the FDA has granted priority review to its supplemental New Drug Application (sNDA) for kidney cancer drug Cabomteyx.

                  Swarup Gupta headshot

                  Foreign Stock Roundup: Roche Gets FDA Nod for Zika Test, Shell to Buy NewMotion

                  Foreign markets remain undeterred by discouraging events, notching up weekly gains.

                    Merck Will Not Seek Approval for CETP Inhibitor Anacetrapib

                    Merck (MRK) is not seeking approval for its CETP inhibitor anacetrapib, which it had developed for cholesterol management.

                      Mylan Gets Complete Response Letter For Biosimilar Neulasta

                      Mylan (MYL) suffered a setback following the FDA's CRL for the company's BLA for MYL-1401H, a proposed biosimilar of Neulasta.

                        Clovis (CLVS) Submits sNDA for Ovarian Cancer Drug Rubraca

                        Clovis submitted a sNDA to the FDA for expansion of Rubraca's label in maintenance treatment for ovarian cancer patients who are in a partial or complete response to platinum-based chemotherapy.

                          AstraZeneca's Tagrisso Gets Breakthrough Therapy Designation

                          AstraZeneca (AZN) obtained Breakthrough Therapy Designation (BTD) for Tagrisso (osimertinib) for the 1st-line treatment of patients with metastatic epidermal growth factor receptor mutation-positive non-small cell lung cancer.

                            Roche (RHHBY) Receives FDA Approval For Cobas Zika Test

                            The approval of cobas Zika will expands Roche's industry-leading donor screening portfolio for blood-borne diseases.

                              AbbVie (ABBV) Stock Up Almost 17% in One Month: Here's Why

                              AbbVie's (ABBV) shares have gained an impressive 16.7% in the past month supported by a series of positive news for the company in the past few weeks.

                                Allergan's sNDA for Anti-Infective Avycaz Accepted by FDA

                                Allergan (AGN) announced that the FDA has accepted the application for the label expansion of Avycaz to include a new indication and study data.

                                  FDA Accepts Roche's (RHHBY) Application for Adjuvant Perjeta

                                  Roche Holdings AG (RHHBY) announced that the FDA has accepted the company's sBLA and granted Priority Review for breast cancer drug regimen Perjeta

                                    Prothena's Psoriasis Candidate Disappoints in Phase I Study

                                    Prothena Corporation plc (PRTA) announced disappointing results from a phase Ib study of pipeline candidate, PRX003 in psoriasis patients.

                                      Allergan (AGN) Pipeline & New Drugs to Counter Generic Woes

                                      Allergan's key drugs like Botox/Linzess and new drugs are supporting sales. However, Allergan faces generic threat for Namenda franchise and patent challenges for some other branded drugs.

                                        Kite Pharma Triples So Far in 2017: What's Driving the Rally?

                                        Kite Pharma's (KITE) shares have surged 300% so far this year riding on the progress of its CAR-T therapy candidate and a favorable buyout offer from Gilead.

                                          Roche (RHHBY) Gets Approval for Label Expansion of Tecentriq

                                          Roche Holding AG (RHHBY) announced a label expansion of immunotherapy drug Tecentriq for the treatment of non-small cell lung cancer in Europe.

                                            Cancer Space Update: Mixed Week for Pfizer, Roche Falters

                                            Roche again disappointed this week with two studies on Tecentriq being put on partial hold while Pfizer's Bavencio received approval in Europe. TESARO's Zejula moved a step closer to approval.

                                              Arpita Dutt headshot

                                              Pharma Stock Roundup: Pfizer Files Suit against J&J, Supernus Hit by Study Update

                                              Industry heavyweights like Pfizer (PFE) and Johnson & Johnson were in the news this week related to a lawsuit while Glaxo got FDA approval for a key drug.

                                                4 Sell-Ranked Biotech Stocks with Falling Estimates to Avoid

                                                Though the biotech industry is doing well, it's a good idea to avoid a few stocks in the industry which will not prove to be prudent additions to your portfolio.

                                                  How is the Age-Related Macular Degeneration Space Faring Now?

                                                  The Age-Related Macular Degeneration (AMD) space has been in the spotlight of late due to a number of developments.